Journal of Psychoactive Drugs
August 12, 2026
Jennifer S. Jewell, C. James, Joshua C. Black
There is still inconsistency in psychedelic research across the United States. There are gaps in our understanding of the psychedelic community's perception of topics including reasons for use and set/setting. The goal is to utilize these findings to produce better quantitative research, to ask the right questions of the right communities. This qualitative study organized focus groups from...
Annals of emergency medicine
June 30, 2025
Joshua C. Black, Karilynn M Rockhill, Evelyn J Fox et al.
4 citations
Oregon and Colorado have legalized possession of natural psychedelic drugs. We assessed if travel to use psychedelics in decriminalized states is occurring and compared the use patterns of travelers with nontravelers. The National Survey Investigating Hallucinogen Trends is a cross-sectional behavioral survey fielded from April to June 2024 to every US state. The survey asks whether individuals...
International Journal of Mental Health and Addiction
April 1, 2025
Joshua C. Black, Nicole Schow, Hannah L. Burkett et al.
3 citations
Psychedelic-assisted therapy could transform treating psychiatric illness, but harms from exacerbating substance use disorder (SUD) among adults with psychiatric illness using psychedelics have not been studied. A cross-sectional survey in the US was used to test whether Drug Abuse Screening Test scores (DAST-10, validated instrument predicting SUD) were more severe when psychiatric illnesses...
Drug and Alcohol Dependence
March 1, 2025
Joseph J Palamar, Jennifer S. Jewell, Omar El-Shahawy et al.
9 citations
Off-label prescribing of ketamine to treat psychiatric disorders has been increasing, as has recreational use and availability of illicit ketamine. It is important to examine trends in ketamine-related poisonings to inform public health efforts. We examined data from poisonings (exposures) involving ketamine reported to Poison Centers in the US between 2019 and 2023 (n = 1519). Annual trends...
Nature Mental Health
May 1, 2024
Joshua C. Black, Andrew A. Monte, Nabarun Dasgupta et al.
5 citations
The encouraging results of late-phase clinical trials investigating psychedelic-assisted psychotherapy suggests that US Food and Drug Administration approval and subsequent expansion of use is imminent in the USA. Without fit-for-purpose postmarket surveillance to proactively monitor utilization by patients and providers, there is a risk that the real-world benefits of psychedelic-assisted...